title: Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
abstract: Tumor lysis syndrome is a set of life threatening complication that can arise from treatment of high tumor burden, drug sensitive, and rapidly proliferating neoplasm particularly of hematological origin. It is rarely described in patients with solid tumors. We report the first case of tumor lysis syndrome in a man with metastatic renal pelvic transitional cell carcinoma after gemcitabine treatment. Despite aggressive therapy, he died 2 weeks after TLS was diagnosed. Our experience demonstrates that administration of gemcitabine for metastatic renal pelvic transitional cell carcinoma may induce acute tumor lysis syndrome, which necessitates frequent laboratory monitoring and prompt initiation of appropriate therapeutic measures.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, 92 Chung San North Road Section 2, Taipei, Taiwan. lincj@ms1.mmh.org.tw
authors.forename: Cheng-Jui
authors.initials: CJ
authors.lastname: Lin
authors.forename: Ken-Hong
authors.initials: KH
authors.lastname: Lim
authors.forename: Yi-Chou
authors.initials: YC
authors.lastname: Cheng
authors.forename: Han-Hsiang
authors.initials: HH
authors.lastname: Chen
authors.forename: Chih-Jen
authors.initials: CJ
authors.lastname: Wu
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000209:etiology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine